GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (SZSE:300534) » Definitions » Equity-to-Asset

Gansu Longshenrongfa Pharmaceutical Industry Co (SZSE:300534) Equity-to-Asset : 0.46 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gansu Longshenrongfa Pharmaceutical Industry Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Gansu Longshenrongfa Pharmaceutical Industry Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥656 Mil. Gansu Longshenrongfa Pharmaceutical Industry Co's Total Assets for the quarter that ended in Mar. 2024 was ¥1,430 Mil. Therefore, Gansu Longshenrongfa Pharmaceutical Industry Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.46.

The historical rank and industry rank for Gansu Longshenrongfa Pharmaceutical Industry Co's Equity-to-Asset or its related term are showing as below:

SZSE:300534' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.46   Med: 0.88   Max: 0.93
Current: 0.46

During the past 13 years, the highest Equity to Asset Ratio of Gansu Longshenrongfa Pharmaceutical Industry Co was 0.93. The lowest was 0.46. And the median was 0.88.

SZSE:300534's Equity-to-Asset is ranked worse than
65.26% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs SZSE:300534: 0.46

Gansu Longshenrongfa Pharmaceutical Industry Co Equity-to-Asset Historical Data

The historical data trend for Gansu Longshenrongfa Pharmaceutical Industry Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gansu Longshenrongfa Pharmaceutical Industry Co Equity-to-Asset Chart

Gansu Longshenrongfa Pharmaceutical Industry Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 0.84 0.87 0.63 0.47

Gansu Longshenrongfa Pharmaceutical Industry Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.46 0.47 0.47 0.46

Competitive Comparison of Gansu Longshenrongfa Pharmaceutical Industry Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Gansu Longshenrongfa Pharmaceutical Industry Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gansu Longshenrongfa Pharmaceutical Industry Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gansu Longshenrongfa Pharmaceutical Industry Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Gansu Longshenrongfa Pharmaceutical Industry Co's Equity-to-Asset falls into.



Gansu Longshenrongfa Pharmaceutical Industry Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Gansu Longshenrongfa Pharmaceutical Industry Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=633.706/1336.651
=0.47

Gansu Longshenrongfa Pharmaceutical Industry Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=655.847/1430.016
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gansu Longshenrongfa Pharmaceutical Industry Co  (SZSE:300534) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Gansu Longshenrongfa Pharmaceutical Industry Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Gansu Longshenrongfa Pharmaceutical Industry Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Gansu Longshenrongfa Pharmaceutical Industry Co (SZSE:300534) Business Description

Traded in Other Exchanges
N/A
Address
No. 10, Defence Road, Dingyuan Town, Gansu Province, Lanzhou, CHN, 730101
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd is mainly engaged in the pharmaceutical business. It is engaged in the research and development of new drugs, traditional Chinese medicine processing and production. Its products portfolio includes Yuan Hu Zhitong Dripping Pills, Qiwei Wenyang Capsule and Xiaoshuan Tongluo Tablets. Its products are used to adjust gas, promote blood circulation, relieve pain, relieve cough, eliminate phlegm, relieve asthma, clear heat, and dispel dampness, among others.
Executives
Chen Yao Wu Executives
Zhang Jin De Director
Zhang Fan Executives
Kong Jian Feng Executives
Yue Qing Xin Supervisors
Kang Yong Hong Executives

Gansu Longshenrongfa Pharmaceutical Industry Co (SZSE:300534) Headlines

No Headlines